The present invention recommends a new approach of allogenic dendritic-stem cell vaccine platform to treat all kinds of ovarian cancers. It proposes the abundant allogenic donated cord blood source to harvest both dendritic special type and mesenchymal stem cells equilibrated package primed with patient"s tumour antigens for a targeted treatment regime. The individual roles of dendritic cells and mesenchymal stem cells in immunomodulation is exploited in developing this new combinatorial platform of cellular vectors for targeted killing of tumour cells in the patient"s body. The source proposed here in developing the technology is a biological discard and is available in profusion for proposed clinical application. Figure 1
